Gene: MAP2K2 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519807
rs1057519807
MAP2K2
T 0.710 GeneticVariation CLINVAR The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. 24265153

2014
dbSNP: rs1057519807
rs1057519807
MAP2K2
0.710 GeneticVariation BEFREE Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. 25452114

2014
dbSNP: rs1057519808
rs1057519808
MAP2K2
G 0.710 GeneticVariation CLINVAR MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. 24265154

2014
dbSNP: rs1057519808
rs1057519808
MAP2K2
0.710 GeneticVariation BEFREE We also identified the same MEK2-Q60P mutation along with BRAF amplification in a xenograft tumor derived from a second melanoma patient resistant to the combination of dabrafenib and trametinib. 24055054

2013
dbSNP: rs1057519806
rs1057519806
MAP2K2
C 0.700 GeneticVariation CLINVAR The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. 24265153

2014
dbSNP: rs1057519809
rs1057519809
MAP2K2
A 0.700 GeneticVariation CLINVAR The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. 24265153

2014
dbSNP: rs1057519810
rs1057519810
MAP2K2
T 0.700 GeneticVariation CLINVAR The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. 24265153

2014